CN106036912A - Vitamin B composition adopting isotonic deep processing - Google Patents
Vitamin B composition adopting isotonic deep processing Download PDFInfo
- Publication number
- CN106036912A CN106036912A CN201610393286.3A CN201610393286A CN106036912A CN 106036912 A CN106036912 A CN 106036912A CN 201610393286 A CN201610393286 A CN 201610393286A CN 106036912 A CN106036912 A CN 106036912A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- compositions
- group
- intestinal
- perfusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000019156 vitamin B Nutrition 0.000 title claims abstract description 51
- 239000011720 vitamin B Substances 0.000 title claims abstract description 51
- 229930003270 Vitamin B Natural products 0.000 title claims abstract description 50
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 238000012545 processing Methods 0.000 title claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 150000002500 ions Chemical class 0.000 claims description 13
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 12
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 11
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 10
- -1 nicotiamide Chemical compound 0.000 claims description 10
- 230000001105 regulatory effect Effects 0.000 claims description 9
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 6
- 229930003779 Vitamin B12 Natural products 0.000 claims description 6
- 229930003471 Vitamin B2 Natural products 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 6
- 229960002477 riboflavin Drugs 0.000 claims description 6
- 235000019163 vitamin B12 Nutrition 0.000 claims description 6
- 239000011715 vitamin B12 Substances 0.000 claims description 6
- 235000019164 vitamin B2 Nutrition 0.000 claims description 6
- 239000011716 vitamin B2 Substances 0.000 claims description 6
- 235000019158 vitamin B6 Nutrition 0.000 claims description 6
- 239000011726 vitamin B6 Substances 0.000 claims description 6
- 229940011671 vitamin b6 Drugs 0.000 claims description 6
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 5
- 229930003451 Vitamin B1 Natural products 0.000 claims description 5
- 229960002685 biotin Drugs 0.000 claims description 5
- 235000020958 biotin Nutrition 0.000 claims description 5
- 239000011616 biotin Substances 0.000 claims description 5
- 229960000304 folic acid Drugs 0.000 claims description 5
- 235000019152 folic acid Nutrition 0.000 claims description 5
- 239000011724 folic acid Substances 0.000 claims description 5
- 229960003495 thiamine Drugs 0.000 claims description 5
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 5
- 235000010374 vitamin B1 Nutrition 0.000 claims description 5
- 239000011691 vitamin B1 Substances 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 235000001465 calcium Nutrition 0.000 claims description 4
- 229960005069 calcium Drugs 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 108010011485 Aspartame Proteins 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical group [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 2
- 239000004376 Sucralose Substances 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 235000010358 acesulfame potassium Nutrition 0.000 claims description 2
- 229960004998 acesulfame potassium Drugs 0.000 claims description 2
- 239000000619 acesulfame-K Substances 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 239000000605 aspartame Substances 0.000 claims description 2
- 235000010357 aspartame Nutrition 0.000 claims description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 2
- 229960003438 aspartame Drugs 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 229940013618 stevioside Drugs 0.000 claims description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 2
- 235000019202 steviosides Nutrition 0.000 claims description 2
- 235000019408 sucralose Nutrition 0.000 claims description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical group O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 2
- 235000019605 sweet taste sensations Nutrition 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 229920002774 Maltodextrin Polymers 0.000 claims 1
- 239000005913 Maltodextrin Substances 0.000 claims 1
- 229940035034 maltodextrin Drugs 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 abstract description 26
- 239000013589 supplement Substances 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 3
- 239000000047 product Substances 0.000 abstract description 3
- 230000001502 supplementing effect Effects 0.000 abstract description 2
- 235000003599 food sweetener Nutrition 0.000 abstract 2
- 239000003765 sweetening agent Substances 0.000 abstract 2
- 239000000644 isotonic solution Substances 0.000 abstract 1
- 235000008935 nutritious Nutrition 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 description 51
- 239000007788 liquid Substances 0.000 description 43
- 230000010412 perfusion Effects 0.000 description 42
- 229940088594 vitamin Drugs 0.000 description 42
- 229930003231 vitamin Natural products 0.000 description 42
- 235000013343 vitamin Nutrition 0.000 description 42
- 239000011782 vitamin Substances 0.000 description 42
- 230000003204 osmotic effect Effects 0.000 description 31
- 150000003722 vitamin derivatives Chemical class 0.000 description 31
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 26
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 25
- 239000000523 sample Substances 0.000 description 25
- 239000000243 solution Substances 0.000 description 25
- 238000012360 testing method Methods 0.000 description 20
- 238000000034 method Methods 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 239000000463 material Substances 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 12
- 210000000813 small intestine Anatomy 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000031891 intestinal absorption Effects 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 239000013558 reference substance Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 210000004347 intestinal mucosa Anatomy 0.000 description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000004400 mucous membrane Anatomy 0.000 description 5
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000012086 standard solution Substances 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 210000000013 bile duct Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 210000001198 duodenum Anatomy 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000002175 goblet cell Anatomy 0.000 description 3
- 210000003405 ileum Anatomy 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000004088 simulation Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000002552 multiple reaction monitoring Methods 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 239000013062 quality control Sample Substances 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- UCTLRSWJYQTBFZ-UHFFFAOYSA-N Dehydrocholesterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CC=C21 UCTLRSWJYQTBFZ-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000002011 intestinal secretion Anatomy 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- XOTREVBPKJHQEX-UHFFFAOYSA-M sodium;2-(3,3,6,6-tetramethyl-1,8-dioxo-9-phenyl-4,5,7,9-tetrahydro-2h-acridin-10-yl)acetate Chemical compound [Na+].C1C(C)(C)CC(=O)C2=C1N(CC([O-])=O)C(CC(C)(C)CC1=O)=C1C2C1=CC=CC=C1 XOTREVBPKJHQEX-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 238000002207 thermal evaporation Methods 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the field of health products, relates to nutritious supplements and in particular to vitamin B composition for supplementing vitamin B. The vitamin B composition comprises components of vitamin B, an acidity regulator, an ion regulator and a sweetening agent. According to the composition, the acidity regulator and the sweetening agent are added and jointly act to regulate the taste of the vitamin B, meanwhile, the acidity regulator and the ion regulator act to increase the ion concentration of the composition, an isotonic solution is formed, and absorption of the vitamin B is promoted.
Description
Technical field
The present invention relates to field of health care products, be specifically related to a kind of supplementary, especially isotonic deeply at a kind of vitamin B group
The compositions of processing, supplementing for vitamin B group.
Background technology
Vitamin has another name called vitamin, popular from the point of view of, the material i.e. sustained life, is to maintain a healthy necessary class
Organic compound.This kind of material neither constitute the raw material of bodily tissue, is not the source of energy in vivo, but a class is adjusted
Joint material, plays an important role in growth in humans, metabolism, growth course.This kind of material can not synthesize due to internal or
Synthetic quantity is not enough, so while requirement is little, but must be often by food supply.
Vitamin is a huge family, and the vitamin known to present stage just has tens kinds, be broadly divided into fat-soluble and
The big class of water solublity two.Fatsoluble vitamin includes vitamin A. D. E, K, is dissolved in fat and organic solvent, often in fat in food
Class coexists.Can store at liver when absorbing many, as picked-up too much can cause poisoning.And water soluble vitamins includes vitamin B group
And vitamin C, it is dissolved in water, internal can not store.Some material is similar to certain vitamin in chemical constitution, through simple
Metabolic response can be transformed into vitamin, and this type of material is referred to as provitamin, and such as beta-carotene can be changed into vitamin A；7-
Dehydrocholesterol can be changed into vitamin D3；But could be formed through many complicated metabolic responses.The tryptophan of nicotinic acid is the most not
Provitamin can be referred to as.
Vitamin B group is also second vitamin (also make vitamin B, vitamin B miscellaneous or vitamin B is combined group), including dimension
Raw element B1, vitamin B2, vitamin B6, vitamin B12, nicotinic acid, pantothenic acid, folic acid etc..Vitamin B group is to promote internal metabolism,
Indispensable water soluble vitamins when sugar, fat, protein etc. are changed into heat.If lacking vitamin B group, then cell
Function reduces at once, causes dysbolismus, and at this moment human body there will be idle stagnant and inappetence.Vitamin B group can help to maintain
Heart, nervous function, maintain digestive system and the health of skin, participates in energy metabolism, can physical strength reinforcing, nourishing and fit keeping function.
Human body cannot manufacture synthesis vitamin B group voluntarily, it is necessary to additionally supplements.Vitamin B group is widely present in Testa oryzae, bran
In the foods such as skin, yeast, the liver of animal, coarse grain vegetable, but owing to eating method is the most right, almost absorb less than.And anxiety
In life, operating pressure, dietary habit or the use because of some certain drug improperly, add that vitamin B group itself keeps in dark place, is afraid of
Water, To Be Protected from Heat, be afraid of oxidation (how at a temperature of 80 degree be destroyed) and be dissolved in the attribute of water, and the vitamin B group in human body all can be made fast
Speed is consumed.The supplementary of vitamins mainly exists with dosage forms such as tablet, hard capsule, soft capsules and sells at present, should
Class dosage form first has to could enter small intestinal through digestion process in human body and is absorbed, and utilizes speed the highest.And on market
Vitamin oral liquid, owing to there is permeable pressure head with cell, so cell can be caused to bear in absorption process, affect suction simultaneously
Produce effects rate.
Summary of the invention
In view of this, it is an object of the invention to provide the compositions of the isotonic deep processing of a kind of vitamin B group, in order to additionally
Supplement vitamin B group, promote that vitamin B group quickly absorbs and strengthens availability.
For realizing the purpose of the present invention, the present invention adopts the following technical scheme that.
A kind of compositions of the isotonic deep processing of vitamin B group, including vitamin B group, acidity regulator, ion regulating agent,
Sweeting agent.
In a particular embodiment, the present invention uses intestinal perfusion method research osmotic pressure to folk prescription and Compound B vitamin pair
The impact of intestinal absorption.Under the conditions of result shows that hypotonic or height oozes, mucous membrane of small intestine, by damage in various degree, is unfavorable for VB's
Absorb.And 8 kinds of vitamin absorb most preferably under isotonic state, being secondly micro-hypotonic condition (150mOsm/L), in pole, low high is oozed
Under the conditions of absorb the most weak.Compared with folk prescription vitamin absorption, the absorption of compound vitamin is bigger.
Compositions of the present invention acts on the mouth of regulation vitamin B group jointly by addition acidity regulator and sweeting agent
Sense；Acidity regulator increases compositions ion concentration with ion regulating agent effect simultaneously, forms isosmotic solution, promotes that B race dimension is raw
The absorption of element.
Wherein, described vitamin B group includes vitamin B1, vitamin B2, vitamin B6, D-VB5 calcium, biotin, leaf
Acid, nicotiamide, vitamin B12.
In some embodiments, vitamin B1 in described vitamin B group, vitamin B2, vitamin B6, D-VB5 calcium,
Biotin, folic acid, nicotiamide, the weight ratio of vitamin B12 are 3.7:3.5:3.7:7:1.8:0.4:17:8.
During described in compositions of the present invention, acidity regulator is citric acid, tartaric acid, malic acid at least one.
Preferably, described acidity regulator is 1600mg:45.1mg with the weight ratio of vitamin B group.
Ion regulating agent described in compositions of the present invention is sodium bicarbonate, sodium carbonate, lactose, mannitol, Fructus Hordei Germinatus
In dextrin at least one.
Preferably, described ion regulating agent is 2273mg:45.1mg with the weight ratio of vitamin B group.
During described in compositions of the present invention, sweeting agent is sucralose, stevioside, acesulfame potassium, aspartame at least
A kind of.
Preferably, described sweeting agent is 2273mg:45.1mg with the weight ratio of vitamin B group.
In a specific embodiment, in every 80mL compositions, each amounts of components is:
The each component of compositions of the isotonic deep processing of vitamin B group of the present invention prepares after mixing preparation fill sterilizing
Oral liquid.
As shown from the above technical solution, the compositions that the invention provides the isotonic deep processing of a kind of vitamin B group includes B race
Vitamin, acidity regulator, ion regulating agent, sweeting agent.Compositions of the present invention is by adding acidity regulator and sweet taste
Agent acts on the mouthfeel of regulation vitamin B group jointly；It is dense that acidity regulator and ion regulating agent effect simultaneously increases compositions ion
Degree, forms isosmotic solution, promotes the absorption of vitamin B group.
Accompanying drawing explanation
In order to be illustrated more clearly that the embodiment of the present invention or technical scheme of the prior art, below will be to embodiment or existing
In having technology to describe, the required accompanying drawing used is briefly described.
Fig. 1 shows typical color spectrogram (A:210nm；B:426nm), wherein, I: blank intestinal circulation fluid；II: simulation intestinal perfusate；
III: actual intestinal circulation fluid (2h) (III-1: compound vitamin；III-2:VB7；III-3:VB12)；1-VB5；2-VB6；3-
VB1；4-VB3；5-VB9；6-VB7；7-VB12；8-VB2；9-is phenol red；
Fig. 2 shows under 5 osmotic pressuries the changing trend diagram of perfusate volume in small intestinal enteric cavity；
Fig. 3 shows the tissue slice figure of small intestinal after normal small intestine and perfusion, wherein, A: normal group；B: hypotonic-1 (75mOsm/
L)；C: hypotonic-2 (150mOsm/L)；D: isotonic (300mOsm/L)；E: height oozes-1 (450mOsm/L)；F: height oozes-2
(600mOsm/L)。
Detailed description of the invention
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described,
Obviously, described embodiment is only a part of embodiment of the present invention rather than whole embodiments.Based in the present invention
Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under not making creative work premise, all
Belong to the scope of protection of the invention.
In order to be further appreciated by the present invention, below in conjunction with specific embodiment, the present invention will be described in detail
The compositions of the isotonic deep processing of embodiment 1B vitamin
Formula is as follows:
By vitamin B group and electrolyte adjuvant (comprising organic acid source, alkali source), that sweeting agent and purified water are configured to 80mL is molten
Liquid, obtains oral liquid good in taste.
Measuring osmotic pressure by osmotic tester is between 280-320mosm/kg, qualitative for isosmotic solution.
The compositions rat in vivo intestinal absorption characteristic research test of the isotonic deep processing of embodiment 2B vitamin
One, experimental technique,
1. the preparation of solution
1.1Krebs-Ringer ' s enteral nutrient solution (being called for short K-R liquid) preparation
Weigh CaCl respectively20.37g, a small amount of water dissolution of glucose 1.4g, as A liquid；Weigh NaCl7.8g, KCl
0.35g、NaHCO3 1.37g、NaH2PO4 0.32g、MgCl2The a small amount of water dissolution of 0.02g, as B liquid；Confirm that A, B are clear
Clear bright after, the two is mixed, is diluted with water to 1L, with salt acid for adjusting pH to 7.40 and get final product.
1.2 phenol red K-R liquid
Precision weighs phenol red 20mg, dissolves with K-R liquid and is settled to 1L.
The preparation of 1.3 perfusion test liquids
Taking entrance intestinal according to formula described in embodiment 1, intestinal juice is in terms of 250mL, and each concentration of component is respectively VB1
(14.8μg/mL)、VB2(14μg/mL)、VB3(68μg/mL)、VB5(28μg/mL)、VB6(14.8μg/mL)、VB7(144ng/
mL)、VB9(1.6μg/mL)、VB12(32ng/mL)；Weighing appropriate vitamin B1, vitamin B2, vitamin B3 respectively, dimension is raw
Element B 5, vitamin B6, vitamin B7 (2%), FA, vitamin B12 (0.1%) adds the phenol red liquid of K-R, is configured to VB1
(14.8μg/mL)、VB2(14μg/mL)、VB3(68μg/mL)、VB5(28μg/mL)、VB6(14.8μg/mL)、VB7(144ng/
ML), VB9 (1.6 μ g/mL), VB12 (32ng/mL) solution 1L standby.
1.4 blank intestinal circulation perfusates
Treating excess syndrome tests the SD rat (n=6) of front fasting 12h (freely drinking water), and lumbar injection urethane 1.0g/kg, after anesthesia
Fixing.Open abdominal cavity (3-5cm) along ventrimeson, ligature bile duct, rise in duodenum upper end and respectively cut an osculum with ileum lower end, use
Content is rinsed well by the normal saline being preheated to 37 DEG C, intubates, ligation, then with air by normal saline emptying, installs dress
Put.
First make it balance with the flow velocity perfusion 10min of 4.0mL/min phenol red K-R liquid, then flow velocity is adjusted to 2.0mL/
Min, circulates 2h, terminates experiment, obtains blank intestinal circulation perfusate.
The preparation of 1.5 reference substance storing solutions
Precision weighs phenol red reference substance 1mg, is placed in 10mL measuring bottle, dissolves with K-R liquid and be settled to scale, mixes and get final product
Concentration is the phenol red reference substance storing solution of 100 μ g/mL.
2. the foundation of method
2.1LC-MS/MS condition
Chromatographic condition: use ACQUITY UPLC liquid phase systems (Waters Corp., Milford, MA, USA), with
ACQUITYBEH C18column (2.1 × 50mm, 1.7 μm) is for analyzing chromatographic column.
Mass Spectrometry Conditions: using Micromass Quattro MicroTMAPI mass spectrograph, ion source is ESI source, is just carrying out
Ion detection, uses multiple-reaction monitoring (MRM) scan mode.
2.1 ultraviolet spectrophotometry
Detection wavelength: 558nm
Blank: 0.2mol/LNaOH solution
3. intestinal perfusion sample treatment
Taking intestinal perfusion sample, 12000rpm is centrifuged 5min, takes supernatant and crosses 0.45 μm filter membrane, takes subsequent filtrate 100 μ L, add respectively
Enter internal standard (hippuric acid) solution to mix with the blank each 10 μ L of K-R liquid, vortex, use solid phase extraction column to remove the salt in sample
Point, analyze by above-mentioned LC-MS/MS condition sample introduction, the peak area of record determinand, calculate dense according to the standard curve of each material
Degree；Take subsequent filtrate 0.5mL, add 5mL 0.2mol/L NaOH solution, survey absorbance by above-mentioned ultraviolet spectrophotometry condition
Value, calculates phenol red concentration according to phenol red standard curve.
4. Method validation
4.1 specificity
Taking blank intestinal perfusate, simulation intestinal perfusion sample and actual intestinal perfusion sample respectively, 12000rpm is centrifuged 5min, mistake
0.45 μm filter membrane, is operated by " intestinal perfusion sample treatment " method, and whether investigate blank intestinal perfusate has dry to the mensuration of each medicine
Disturb.
4.2 standard curves and the range of linearity
Phenol red: to prepare phenol red series standard solution.Take series standard liquid 0.5mL respectively, add 5mL0.2mol/L NaOH
Solution, with 0.2mol/L NaOH solution as blank, surveys absorbance at 558nm, and with phenol red concentration as abscissa, absorbance is
Vertical coordinate draws standard curve, obtains phenol red standard curve.
Determinand: preparation series mixing reference substance solution.Take blank intestinal perfusate 100 μ L, be separately added into inner mark solution and
The each 10 μ L of above-mentioned series standard solution, vortex mixed, remaining is operated by " intestinal perfusion sample treatment " method, with the concentration of determinand
For abscissa, determinand and internal standard peak area ratio are that vertical coordinate draws standard curve, obtain the standard curve of each material.
4.3 lower limit of quantitation
Take blank intestinal perfusate 100 μ L, add mixed standard solution (concentration is to mark the concentration of bent minimum point) molten with internal standard
The each 10 μ L of liquid, remaining is operated by " intestinal perfusion sample treatment " method, carries out 6 sample analyses, as calculating often according to standard curve
This concentration, calculates RSD.
4.4 precision and accuracy
Prepare the reference substance solution of basic, normal, high 3 concentration respectively.Take blank intestinal perfusate 100 μ L, be separately added into internal standard
Solution and each 10 μ L of above-mentioned reference substance solution, prepare the Quality control samples of basic, normal, high 3 concentration, and remaining presses " intestinal perfusion sample
Product process " method operation, each concentration carries out 6 sample analyses, continuous three days, calculates sample concentration according to standard curve, and count
Calculate assay method accuracy, in a few days with day to day precision.
4.5 extraction recovery
The Quality control samples of basic, normal, high 3 concentration, each concentration is prepared by method below " precision and accuracy " item
Carry out 6 sample analyses.Separately take blank intestinal perfusate 100 μ L, by the blank extracting solution of method preparation below " precision and accuracy " item,
Adding inner mark solution and each 10 μ L of standard series concentration in the extracting solution obtained, vortex mixes, sample introduction analysis.After extracting
The ratio of the chromatographic peak peak area that chromatographic peak peak area obtains with un-extracted direct injected calculates extraction recovery.
4.6 study on the stability
Investigate medicine respectively in phenol red K-R liquid and the stability in blank intestinal perfusate: respectively with phenol red K-R liquid with blank
Intestinal perfusate preparation perfusion test liquid (n=3), puts in 37 DEG C of water-baths, respectively at 0,0.5,1,1.5,2h sampling, by " intestinal perfusion
Sample treatment " method processes under item, sample introduction analysis, according to regression equation calculation each sample concentration, remains percentage ratio table with medicine
Show the stability of medicine.
4.7 matrix effect
The quality-control sample of basic, normal, high 3 concentration, each concentration 6 sample is prepared respectively with flowing and blank intestinal perfusate
This, carry out LC-MS/MS analysis, records peak area, calculates matrix effect.
5. rat is tested in body intestinal absorption
5.1 intestinal perfusion methods
Treating excess syndrome tests the SD rat (n=6) of front fasting 12h (freely drinking water), and lumbar injection urethane 1.0g/kg, after anesthesia
Fixing.Open abdominal cavity (3-5cm) along ventrimeson, ligature bile duct, rise in duodenum upper end and respectively cut an osculum with ileum lower end, use
Content is rinsed well by the normal saline being preheated to 37 DEG C, intubates, ligation, then with air by normal saline emptying, installs dress
Put.
Take perfusion test liquid (being preheated to 37 DEG C) 100mL, first make it balance with the flow velocity perfusion 10min of 4.0mL/min, then
Flow velocity is adjusted to 2.0mL/min, starts timing, respectively at 0,0.5,1,1.5,2h sample 1.5mL, add phenol red K-R liquid simultaneously
1.5mL, experiment puts to death rat after terminating.
The regulation of 5.2 perfusate osmotic pressuries
Osmotic pressure depend mainly on the size of the number of particles of solute in solution, by regulation " the system of 1.3 perfusion test liquids
Standby " in K-R liquid, the amount preparation of NaCl has the perfusion test liquid (table 1) of different osmotic under item.
The addition of NaCl in the K-R liquid of table 1 different osmotic
The impact that compound vitamin is absorbed by 5.3 osmotic pressuries
The absorption of compound vitamin: operate by under " preparations of 1.3 perfusion test liquids " item, uses the K-R of different osmotic
Liquid prepares the perfusion test liquid of compound vitamin respectively, and the concentration being configured to each composition is respectively as follows: VB1 (14.8 μ g/mL), VB2
(14μg/mL)、VB3(68μg/mL)、VB5(28μg/mL)、VB6(14.8μg/mL)、VB7(144ng/mL)、VB9(1.6μg/
mL)、VB12(32ng/mL).Carry out intestinal perfusion, investigate osmotic pressure to the impact of every kind of vitamin absorption in compound recipe.
The impact on folk prescription vitamin absorption of 5.4 osmotic pressuries
The absorption of folk prescription vitamin: operate by under " preparations of 1.3 perfusion test liquids " item, uses the K-R of different osmotic
Liquid prepares the perfusion test liquid of folk prescription vitamin respectively, is respectively as follows: VB1 (14.8 μ g/mL), VB2 (14 μ g/mL), VB3 by concentration
(68μg/mL)、VB5(28μg/mL)、VB6(14.8μg/mL)、VB7(4μg/mL)、VB9(1.6μg/mL)、VB12(2μg/mL)。
Operate by under " 5.1 intestinal perfusion method " item, carry out intestinal perfusion, investigate the osmotic pressure impact on every kind of vitamin absorption.
6. data analysis
In intestinal perfusion experiment, intestinal segment not only absorbs the drug but also absorbs moisture；On the other hand, the water of intestinal tube secretion is likely to
Entering enteric cavity, result causes perfusate volume to change, therefore uses and do not indicated sample volume by the phenol red of intestinal absorption.
With the logarithm (lnX) of little enteral residual drug, t regression plot sample time, the slope of gained straight line are absorption
Speed constant Ka(h-1).Calculate absorption halftime t1/2(h) and PA.
Two, experimental result
1.1 specificity
The typical color spectrogram of blank intestinal circulation fluid, simulation intestinal perfusate and actual intestinal circulation fluid is as shown in Figure 1.Can by Fig. 1
Knowing, endogenous material and metabolite do not disturb 8 kinds of vitamin and phenol red mensuration.
1.2 standard curves and the range of linearity
With the concentration of reference substance as abscissa, peak area is that vertical coordinate draws standard curve, obtains the standard curve of each material,
As shown in table 2.
28 kinds of vitamin of table and phenol red mark song curve
As shown in Table 2,8 kinds of vitamin and phenol red good in the concentration range internal linear relation investigated, correlation coefficient r is equal
More than 0.999.
In 1.3 days, day to day precision and accuracy
Basic, normal, high 3 concentration of each material in a few days, that day to day precision and accuracy investigate result is as shown in table 3.
The each composition to be measured of table 3 in a few days, day to day precision and accuracy result
As shown in table 3, each material is in a few days respectively less than 3.68% with day to day precision, accuracy 95.0～104.4% it
Between, all meet biological sample analysis requirement.
1.4 stability
Having investigated perfusion test liquid respectively in the stability of 37 DEG C of water-bath 2h, the quality-control sample of basic, normal, high 3 concentration is 4
DEG C place 12h, three freeze-thaw cycle ,-80 DEG C of stability placing 7d.Result is as shown in table 4, table 5.
Table 4 determinand places the stability (mean ± SD, n=3) of 2h in 37 DEG C of K-R buffer
Table 5 determinand stability (mean ± SD, n=3) under condition of storage
From table 4 and 5, after the perfusion test liquid of each material places 2h in 37 DEG C of water-baths, residue percentage ratio is 99.1
～101.0%, have good stability；Intestinal circulation perfusate 4 DEG C places 12h, three freeze-thaw cycle ,-80 DEG C of placement 7d, its response rate
Between 93.8～105.0%, have good stability.
The selection of embodiment 3 dosage
Containing crude drug: VB1 (3.7mg), VB2 (3.5mg), nicotiamide (17mg), D-in per unit vitamin B group compositions
Calcium pantothenate (7mg), VB6 (3.7mg), biotin (2%, 1.8mg), folic acid (0.4mg), VB12 (0.1%, 8mg).
Human small intestine's liquid is long-pending is about 250mL, according to the cubage perfusate of composition each in vitamin B group compositions
Concentration, wherein VB1 (about 14.8 μ g/mL), VB2 (about 14 μ g/mL), VB3 (about 68 μ g/mL), VB5 (about 28 μ g/mL), VB6 are (about
14.8 μ g/mL), VB7 (about 144ng/mL), VB9 (about 1.6 μ g/mL), VB12 (about 32ng/mL).
Wherein the content of VB7 with VB12 is less, uses HPLC method to be difficult to accurately detect.Therefore, folk prescription vitamin is being investigated
During absorption, suitably increase its perfusion concentration, to reach testing requirement.After preliminary experiment is investigated, guaranteeing before Accurate Determining
Put, make perfusion concentration try one's best close to the concentration in oral liquid, finally determine that perfusion concentration is 4 μ g/mL (VB7) and 2 μ g/mL
(VB12)。
The variation tendency of embodiment 4 perfusate volume
In intestinal perfusing course, intestinal also can absorb moisture while absorbing vitamin；On the other hand, intestinal secretion
Water also can enter enteric cavity, thus causes perfusate volume in enteric cavity to change, and therefore, the concentration only measuring medicine cannot be accurate
Weigh the absorbtivity of small intestinal, therefore use not by the phenol red volume correcting perfusate of intestinal absorption.According to formula (1), utilize
The volume of the phenol red concentration correction perfusate recorded, the volume versus time curve of perfusate under 5 osmotic pressuries, result is such as
Shown in Fig. 2.
Wherein, n is the n-th sample point；C0For concentration phenol red in perfusion test liquid or in phenol red K-R liquid；CnIt is n-th
Phenol red concentration measured by time point.
Result shows, under the conditions of hypotonic, perfusate volume reduces in time；Under the conditions of height oozes, perfusate volume with
Time increases, it may be possible to small intestinal absorbs moisture or to secretion moisture in enteric cavity from enteric cavity, thus the perfusate that low high is oozed to
Isotonic regulation.And under isotonic state, perfusate change in volume is less, it may be possible to owing to the normal physiological of moisture is absorbed by small intestinal
Or a small amount of moisture is by thermal evaporation.
The impact that compound vitamin is absorbed by embodiment 5 osmotic pressure
1, intestinal perfusion method
Treating excess syndrome tests the SD rat (n=6) of front fasting 12h (freely drinking water), and lumbar injection urethane 1.0g/kg, after anesthesia
Fixing.Open abdominal cavity (3-5cm) along ventrimeson, ligature bile duct, rise in duodenum upper end and respectively cut an osculum with ileum lower end, use
Content is rinsed well by the normal saline being preheated to 37 DEG C, intubates, ligation, then with air by normal saline emptying, installs dress
Put.
Take perfusion test liquid (being preheated to 37 DEG C) 100mL, first make it balance with the flow velocity perfusion 10min of 4.0mL/min, then
Flow velocity is adjusted to 2.0mL/min, starts timing, respectively at 0,0.5,1,1.5,2h sample 1.5mL, add phenol red K-R liquid simultaneously
1.5mL, experiment puts to death rat after terminating.
The impact on intestinal absorption of 5.2 osmotic pressuries
By adjusting the addition of NaCl in K-R liquid, prepare the perfusion test liquid of 5 kinds of different osmotic respectively, by above-mentioned
Intestinal perfusion compares each vitamin absorbing state under 5 osmotic pressuries in B group vitamin isotonic deep processing compositions, result
As shown in table 6.
Table 6 compound vitamin absorbing state under 5 osmotic pressuries
Note "---" is negative absorption
Wherein the content of B7 with B12 is less, it is impossible to measure, and remaining each composition absorbing state under the conditions of isotonic is best,
Secondly it is micro-hypotonic condition (150mOsm/L), absorbs the most weak under the conditions of pole low high is oozed.
The impact on folk prescription vitamin absorption of embodiment 6 osmotic pressure
8 kinds of vitamin absorbing state under 5 osmotic pressuries is as shown in table 7, each composition absorption feelings under the conditions of isotonic
Preferably secondly condition is micro-hypotonic condition (150mOsm/L), absorbs the most weak under the conditions of pole low high is oozed.
The 78 kinds of folk prescription vitamin of table absorbing state under 5 osmotic pressuries
Note "---" is negative absorption
Result shows, either compound recipe or folk prescription, and each composition absorbing state under the conditions of isotonic is best, is secondly micro-
Hypotonic condition (150mOsm/L), absorbs the most weak under the conditions of pole low high is oozed.Compared with absorption with folk prescription vitamin, big in compound recipe
The absorption of some vitamin increases, and there are some researches show that take multiple vitamin B group is conducive to it to absorb, with this result of study simultaneously
Identical.Therefore, when (1) supplements vitamin B group, compound vitamin is taken preferable；(2) when vitamin B group is taken with isotonic state,
Absorb optimal.
The impact on mucous membrane of small intestine of embodiment 7 osmotic pressure
By adjusting the addition of NaCl in K-R liquid, prepare the perfusion test liquid of 10 kinds of different osmotic respectively, by above-mentioned
Method investigates the osmotic pressure impact on intestinal absorption.
Small intestinal pathological section after preparation different osmotic sample perfusion, with normal small intestine section for comparison, compares osmotic pressure
Impact (blood vessel structure changes, with or without hyperemia, swelling phenomenon etc.) on small intestinal.
The tissue slice figure of the small intestinal after different osmotic superfusion and normal small intestine is as shown in Figure 3.Small intestine meridian is hypotonic
After superfusion (Fig. 3 B, 3C), the goblet cell on intestinal mucosa increases, thus adds the absorption of moisture in enteric cavity, to increase
Add the osmotic pressure of solution in enteric cavity；On the other hand, the moisture of absorption makes mucous membrane of small intestine fill, and causes the annular wrinkle on mucous membrane of small intestine
Pleat and fine hair arrangement closely, are unfavorable for the motion of fine hair, and reduce the area of intestinal mucosa and medicament contact, thus weaken little
The intestinal absorption to medicine.After small intestine meridian hyperosmotic solution perfusion (Fig. 3 E, 3F), the goblet cell on intestinal mucosa reduces, and intestinal mucosa wrinkles
Contracting is serious, it may be possible to owing to small intestinal will drain in enteric cavity outside moisture, to reduce the osmotic pressure of perfusate in enteric cavity；On intestinal mucosa
Fine hair shrinkage is serious, is tightly attached to mucomembranous surface, it is difficult to flexible and swing, is unfavorable for the absorption of medicine.(75mOsm/ is oozed extremely low
L, Fig. 3 B) or high ooze (600mOsm/L, Fig. 3 F) under the conditions of, on the one hand a little mucosa ruptures and comes off, and is that mucous membrane of small intestine is subject to
Damage, weaken absorption function；On the other hand the medicine absorbed may be caused again to discharge, thus produce negative absorption.But, small intestine meridian
After isosmotic solution perfusion (Fig. 3 D), intestinal mucosa ruptures, more complete；Goblet cell is uniformly distributed, and fine hair arrangement is sparse, has
It is beneficial to motion and the absorption of medicine of fine hair.
Claims (10)
1. a compositions for the isotonic deep processing of vitamin B group, including vitamin B group, acidity regulator, ion regulating agent, sweet
Taste agent.
Compositions the most according to claim 1, described vitamin B group include vitamin B1, vitamin B2, vitamin B6,
D-VB5 calcium, biotin, folic acid, nicotiamide, vitamin B12.
Compositions the most according to claim 1 and 2, vitamin B1 in described vitamin B group, vitamin B2, vitamin B6,
D-VB5 calcium, biotin, folic acid, nicotiamide, the weight ratio of vitamin B12 are 3.7:3.5:3.7:7:1.8:0.4:17:8.
Compositions the most according to claim 1, described acidity regulator is in citric acid, tartaric acid, malic acid at least one
Kind.
Compositions the most according to claim 1, described acidity regulator is 1600mg with the weight ratio of vitamin B group:
45.1mg。
Compositions the most according to claim 1, described ion regulating agent is sodium bicarbonate, sodium carbonate, lactose, mannose
In alcohol, maltodextrin at least one.
Compositions the most according to claim 1, described ion regulating agent is 2273mg with the weight ratio of vitamin B group:
45.1mg。
Compositions the most according to claim 1, described sweeting agent is sucralose, stevioside, acesulfame potassium, aspartame
In at least one.
Compositions the most according to claim 1, described sweeting agent is 2273mg:45.1mg with the weight ratio of vitamin B group.
Compositions the most according to claim 1, in every 75mL compositions, each amounts of components is:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610393286.3A CN106036912A (en) | 2016-06-02 | 2016-06-02 | Vitamin B composition adopting isotonic deep processing |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610393286.3A CN106036912A (en) | 2016-06-02 | 2016-06-02 | Vitamin B composition adopting isotonic deep processing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106036912A true CN106036912A (en) | 2016-10-26 |
Family
ID=57170468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610393286.3A Pending CN106036912A (en) | 2016-06-02 | 2016-06-02 | Vitamin B composition adopting isotonic deep processing |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106036912A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030203072A1 (en) * | 2002-04-26 | 2003-10-30 | Team Nrg, Inc. | Rehydration beverage |
| US20050095320A1 (en) * | 2003-10-29 | 2005-05-05 | Richard Botteri | [An Isotonic Sports Drink for Female Athletes Fortified with Iron, Calcium and Essential Vitamins for Use in Rehydration and Nutrition During Execise and Competition] |
| CN1628561A (en) * | 2004-10-25 | 2005-06-22 | 上海长海医院 | Combination for releasing lassitude and its preparation method and uses |
| CN102318820A (en) * | 2011-08-17 | 2012-01-18 | 无锡爱内特营养保健品科技有限公司 | Nutrient for improving human body adsorption of nutrient component and bioavailability |
| CN102526333A (en) * | 2011-01-04 | 2012-07-04 | 统欣生物科技股份有限公司 | Composition for regulating blood fat and protecting heart and blood vessels |
-
2016
- 2016-06-02 CN CN201610393286.3A patent/CN106036912A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030203072A1 (en) * | 2002-04-26 | 2003-10-30 | Team Nrg, Inc. | Rehydration beverage |
| US20050095320A1 (en) * | 2003-10-29 | 2005-05-05 | Richard Botteri | [An Isotonic Sports Drink for Female Athletes Fortified with Iron, Calcium and Essential Vitamins for Use in Rehydration and Nutrition During Execise and Competition] |
| CN1628561A (en) * | 2004-10-25 | 2005-06-22 | 上海长海医院 | Combination for releasing lassitude and its preparation method and uses |
| CN102526333A (en) * | 2011-01-04 | 2012-07-04 | 统欣生物科技股份有限公司 | Composition for regulating blood fat and protecting heart and blood vessels |
| CN102318820A (en) * | 2011-08-17 | 2012-01-18 | 无锡爱内特营养保健品科技有限公司 | Nutrient for improving human body adsorption of nutrient component and bioavailability |
Non-Patent Citations (1)
| Title |
|---|
| GRANTMENG0618: "《百度文库》", 24 October 2013 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Trommelen et al. | Presleep dietary protein-derived amino acids are incorporated in myofibrillar protein during postexercise overnight recovery | |
| Beelen et al. | Protein coingestion stimulates muscle protein synthesis during resistance-type exercise | |
| Buckley et al. | Bovine colostrum supplementation during endurance running training improves recovery, but not performance | |
| Thureen et al. | Effect of low versus high intravenous amino acid intake on very low birth weight infants in the early neonatal period | |
| CN103889411B (en) | For adjusting the composition and method of metabolic pathway | |
| Mccormick et al. | The impact of morning versus afternoon exercise on iron absorption in athletes | |
| CN106983854A (en) | For PKU and the PROVON 190 medicinal food of the nutritional control of other metabolic diseases | |
| US20090017167A1 (en) | Mixture and beverage made therefrom for protecting cellular hydration | |
| ES2758179T3 (en) | Procedure to produce personalized nutrient supplementation | |
| Helal et al. | Comparison between the effect of sucralose and sodium saccharin on some physiological parameters in male albino rats | |
| Hugi et al. | Insulin-dependent glucose utilization in intensively milk-fed veal calves is modulated by supplemental lactose in an age-dependent manner | |
| US20060188627A1 (en) | Isomaltulose or trehalose containing comestibles for sustained carbohydrate energy release and increased fat oxidation | |
| Egan et al. | Zinc absorption in women: comparison of intrinsic and extrinsic stable-isotope labels | |
| Evans et al. | Acute effects of ingesting glucose solutions on blood and plasma volume | |
| Reyes-Izquierdo et al. | The Effect of Elevatp™ on Exercise Output: A Single Dose | |
| Wang et al. | Association between insulin-like growth Factor-1 and uric acid in Chinese children and adolescents with idiopathic short stature: a cross-sectional study | |
| US20210372991A1 (en) | Detection and modification of gut microbial population | |
| Green et al. | Are patients with primary biliary cirrhosis hypermetabolic? A comparison between patients before and after liver transplantation and controls | |
| CN111068074A (en) | Galactose oral composition and application thereof | |
| CN103550398B (en) | Composition for relieving fatigue as well as preparation method and medical application thereof | |
| US20120253014A1 (en) | Preventive agent for atopic dermatitis | |
| Rowlands et al. | L-Arginine but not L-glutamine likely increases exogenous carbohydrate oxidation during endurance exercise | |
| CN106036912A (en) | Vitamin B composition adopting isotonic deep processing | |
| EP3574912A1 (en) | Composition for treating diabetic disease | |
| US20220401387A1 (en) | Compositions and methods affecting exercise performance |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161026 |